Analyzing CYTO’s price-to-book ratio for the last quarter

In the current trading session, Altamira Therapeutics Ltd’s (CYTO) stock is trading at the price of $2.30, a gain of 9.48% over last night’s close. So, the stock is trading at a price that is -97.74% less than its 52-week high of $101.60 and 22.29% better than its 52-week low of $1.88. Based on the past 30-day period, the stock price is -35.83% below the high and +20.94% above the low.

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CYTO’s SMA-200 is $9.32.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


How does Altamira Therapeutics Ltd (CYTO) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.

Altamira Therapeutics Ltd (NASDAQ: CYTO) Ownership Details

I will give a breakdown of the key shareholders in Altamira Therapeutics Ltd (CYTO). Recent figures show that the company’s insiders hold 0.17% of shares. A total of 8 institutional investors hold shares in the company, making 2.82% of its stock and 2.82% of its float.

Jun 29, 2023, it was reported that the Company’s largest institutional holder is Citadel Advisors Llc holding total of 72931.0 shares that make 0.92% of the company’s total number of shares and are currently priced at 0.16 million.

The securities firm Morgan Stanley holds 500.0 shares of CYTO, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.01%, and the holding percentage of shares is valued at 1115.0.

An overview of Altamira Therapeutics Ltd’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Altamira Therapeutics Ltd (CYTO) traded 274,861 shares per day, with a moving average of $2.82 and price change of -0.54. With the moving average of $4.26 and a price change of -0.09, about 1,145,664 shares changed hands on average over the past 50 days. Finally, CYTO’s 100-day average volume is 597,935 shares, alongside a moving average of $4.40 and a price change of -4.51.

Related Posts